ライフサイエンスコーパス: germ cell tumor

1 ion, and 15 (50%) had recurrence with viable germ cell tumor.

2 linical events in patients with a history of germ cell tumor.

3 ma, rhabdomyosarcoma, a breast cancer, and a germ cell tumor.

4 earched using the terms testicular cancer or germ cell tumors.

5 ights into how cell identity is lost in some germ cell tumors.

6 icities of initial treatments for testicular germ cell tumors.

7 reading frame and is expressed in human male germ cell tumors.

8 at occur in vivo, particularly in testicular germ cell tumors.

9 arcoma, mesothelioma, melanoma, gastric, and germ cell tumors.

10 therapies are being explored in early stage germ cell tumors.

11 so with the different histologic subtypes of germ cell tumors.

12 r potential toxicities, in the management of germ cell tumors.

13 are continuing to identify risk factors for germ cell tumors.

14 nt pre-clinical and clinical developments in germ cell tumors.

15 by autologous stem-cell transplantations for germ cell tumors.

16 d-dose etoposide as salvage chemotherapy for germ cell tumors.

17 in patients with mastocytosis, leukemia, and germ cell tumors.

18 to overcome the rapid proliferation seen in germ cell tumors.

19 ure teratoma as one component of their mixed germ cell tumors.

20 expressed in human pluripotent cells and in germ cell tumors.

21 loss in one or more components of the mixed germ cell tumors.

22 umors that often coexist with other types of germ cell tumors.

23 nt as in mice and a potential involvement in germ cell tumors.

24 with pathological stage II or III testicular germ cell tumors.

25 seminomatous and nonseminomatous testicular germ cell tumors.

26 ute myeloid leukemia (AML), mastocytosis and germ cell tumors.

27 in patients with mastocytosis, leukemia, and germ cell tumors.

28 ich can form noninfectious particles in some germ cell tumors.

29 citabine in heavily pretreated patients with germ cell tumors.

30 rate and survival in patients with poor-risk germ cell tumors.

31 standard treatment for advanced disseminated germ cell tumors.

32 essed in specific histopathologic subsets of germ cell tumors.

33 e patients with extragonadal nonseminomatous germ cell tumors.

34 dren with standard risk medulloblastomas and germ cell tumors.

35 approach from the Brazilian GCT-99 study on germ cell tumors.

36 bility in flies, worms, zebrafish, and human germ cell tumors.

37 ldren with newly diagnosed non-germinomatous germ cell tumors.

38 ldren with newly diagnosed non-germinomatous germ cell tumors.

39 ly as either seminomas or nonseminomas/mixed germ cell tumors.

40 reatment of certain categories of testicular germ cell tumors.

41 infertility and are associated with ovarian germ cell tumors.

42 in only 35% of patients with newly diagnosed germ-cell tumors.

43 ller men are at increased risk of testicular germ-cell tumors.

44 exposure to pesticides and risk of childhood germ-cell tumors.

45 (testicular teratocarcinomas) and low in non-germ-cell tumors.

46 , central nervous system tumors, or renal or germ-cell tumors.

47 nd is a key determinant of oncogenic fate in germ-cell tumors.

48 g criteria: (1) history of malignant ovarian germ cell tumor; (2) treatment with surgery plus platinu

49 eat success in the treatment of disseminated germ cell tumors, 20% of patients are incurable and beco

50 brile neutropenia following chemotherapy for germ cell tumors (44.5% v 36.0%).

51 a or primitive neuroectodermal tumors, 57.8; germ cell tumors, 63.5; ependymoma or high-grade glioma,

52 135 patients with progressive, disseminated germ cell tumors after cisplatin-etoposide-based combina

53 ticide exposure in the workplace and risk of germ-cell tumors among offspring.

54 hown activity as single agents in refractory germ cell tumors and can be combined with manageable tox

55 cause of cisplatin resistance in testicular germ cell tumors and may also be implicated in ovarian a

56 Expression of MBD3L2 was found in germ cell tumors and some somatic tissues.

57 in the geographic and ethnic distribution of germ cell tumors and the changing incidence of seminoma

58 The genetic nature of testicular germ cell tumors and the molecular mechanisms underlying

59 lude thyroid, thymic and lymph node lesions; germ cell tumors and vascular lesions.

60 In addition, germ-cell tumors and a few somatic tumors show detectabl

61 reproductive system, including proliferative germ-cell tumors and uterine masses that express neurona

62 c pollution in relation to retinoblastoma or germ cell tumors, and both cancers are rare, these findi

63 M50B expression is deregulated in testicular germ cell tumors, and loss of imprinting occurs frequent

64 umor, 17 had malignant astrocytoma, nine had germ-cell tumor, and 21 had other types of tumors) were

65 Germ cell tumors are a heterogeneous group of neoplasms

66 ations in the rising incidence of testicular germ cell tumors are beginning to be observed in certain

67 Gonadal and nongonadal germ cell tumors are derived from primordial germ cells

68 Germ cell tumors are highly treatable, but significant c

69 opriate Phf7 expression, is also observed in germ cell tumors arising from the loss of bag of marbles

70 OCT4 is commonly expressed in germ-cell tumors as well as putative cancer stem cells i

71 fying potentially new serum tumor markers in germ cell tumor, as well as the role of the traditional

72 Odds ratios for childhood germ-cell tumors associated with maternal exposures befo

73 Patients with germ cell tumors believed to be incurable with chemother

74 whether the humoral immune response affects germ cell tumor biology.

75 HERV-K viral genes are highly transcribed in germ cell tumors but are transcribed to lower or undetec

76 ic, normal fetal kidney, and endometrial and germ cell tumors) but little sequence similarity to othe

77 In germ cell tumors, carboplatin was inferior because of lo

78 ssion profiles of human ES cell lines, human germ cell tumor cell lines and tumor samples, somatic ce

79 We analyzed three pairs of testicular germ cell tumor cell lines using Affymetrix expression m

80 Analysis of testicular germ cell tumor clinical samples by quantitative reverse

81 between mature teratoma and all of the other germ cell tumor components were seen in 10 of 14 tumors

82 ogenetic relationship of teratoma with other germ cell tumor components.

83 uman spermatogenesis and in human testicular germ cell tumors considered to be precursors of EC.

84 Germ cell tumors constitute the most curable of all canc

85 egies for the different stages of testicular germ cell tumors continue to be defined and refined, as

86 ionally, risk factors for the development of germ cell tumors continue to be identified.

87 tissue specimens and cell culture models of germ cell tumors continues.

88 Immunohistochemical results from 43 germ cell tumors demonstrated increased FGF4 expression

89 ifferentiation may be of predictive value in germ cell tumor diagnosis.

90 The extragonadal germ cell tumors (EGCTs) represent a unique entity, and

91 rapeutic role for 4HPR mediated apoptosis in germ cell tumors even when a maturation block is present

92 ent studies on the molecular pathogenesis of germ cell tumors further highlight the complexity of the

93 t-line treatment in patients with metastatic germ cell tumor (GCT) and poor-prognostic clinical featu

94 Purpose Patients with relapsed metastatic germ cell tumor (GCT) can be cured with second-line and

95 Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associ

96 atoma in patients with metastatic testicular germ cell tumor (GCT) is of unknown prognostic significa

97 Germ cell tumor (GCT) is the most common malignancy in y

98 Of these, 269 (51%) had either viable germ cell tumor (GCT) or teratoma present in the RPLND s

99 chorionic gonadotrophin in the management of germ cell tumor (GCT) patients is a biochemical reflecti

100 lus etoposide [E] with stem-cell support) in germ cell tumor (GCT) patients predicted to have a poor

101 ring the first two cycles of chemotherapy in germ cell tumor (GCT) patients was initially reported by

102 es were conducted on 488 North American male germ cell tumor (GCT) survivors in relation to cumulativ

103 MT of a somatic teratomatous component in a germ cell tumor (GCT) to a histology that is identical t

104 alysis of patients with late relapse (LR) of germ cell tumor (GCT) with reports on clinical character

105 ubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standar

106 Malignant germ cell tumors (GCT) of childhood are rare and heterog

107 r clinicopathologic heterogeneity, malignant germ cell tumors (GCT) share molecular abnormalities tha

108 chemotherapy (HDCT) as salvage modality for germ cell tumors (GCT) were previously described, and a

109 After resection, 26 patients had germ cell tumors (GCT), 12 had malignant transformation

110 eatment in patients with newly diagnosed CNS germ cell tumors (GCT), using etoposide plus cisplatin f

111 icity than the classic markers of testicular germ cell tumors (GCTs) and are applicable toward both s

112 y sensitivity, most patients with metastatic germ cell tumors (GCTs) are cured with cisplatin-based c

113 Germ cell tumors (GCTs) are the most common cancer in me

114 The anterior mediastinal germ cell tumors (GCTs) are the most common EGCT.

115 Male germ cell tumors (GCTs) are uniquely sensitive to cispla

116 Adult male germ cell tumors (GCTs) arise by transformation of totip

117 are rare in children, with pineoblastoma and germ cell tumors (GCTs) being the most common.

118 Pediatric germ cell tumors (GCTs) commonly arise at extragonadal s

119 Adult male germ cell tumors (GCTs) comprise distinct groups: semino

120 Male adult germ cell tumors (GCTs) comprise two major histologic gr

121 ssion by immunohistochemistry in sections of germ cell tumors (GCTs) from 10 patients with testicular

122 tes for children with extracranial malignant germ cell tumors (GCTs) have increased significantly.

123 Some germ cell tumors (GCTs) in men develop into hematologic

124 rain mice are predisposed to developing male germ cell tumors (GCTs) of the testes.

125 Germ cell tumors (GCTs) of the testis are the predominan

126 Adult human male germ cell tumors (GCTs) provide a unique opportunity to

127 ternal dietary intake patterns and pediatric germ cell tumors (GCTs) using principal components analy

128 CRs) in two thirds of patients with advanced germ cell tumors (GCTs) who relapsed after first-line ch

129 py, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous throm

130 In men with metastatic germ cell tumors (GCTs), risk-directed treatment is dete

131 12q22 region is recurrently deleted in male germ cell tumors (GCTs), suggesting that this site may h

132 e to chemotherapy for patients with advanced germ cell tumors (GCTs), to evaluate different methods b

133 herapy for patients with relapsed testicular germ cell tumors (GCTs).

134 minomas and dysgerminomas, a subset of human germ cell tumors (GCTs).

135 irst-line therapy in patients with poor-risk germ cell tumors (GCTs).

136 n has previously been reported in human male germ cell tumors (GCTs).

137 therapy (HDCT) in the management of advanced germ cell tumors (GCTs).

138 e management of central nervous system (CNS) germ cell tumors (GCTs).

139 Germ-cell tumors (GCTs), which arise from pluripotent em

140 , intermediate immature teratomas, malignant germ cell tumors [GCTs (dysgerminomas, endodermal sinus

141 genome-wide association study for testicular germ cell tumor, genotyping 298,782 SNPs in 979 affected

142 our patients with testicular nonseminomatous germ cell tumor had low-volume retroperitoneal metastase

143 The medical treatment of advanced testicular germ cell tumors has changed over the past 30 years, wit

144 Patients with clinical stage I testicular germ cell tumors have been managed with adjuvant radioth

145 wide spectrum of human neoplasms, including germ cell tumors, high-grade and low-grade carcinomas an

146 90 to 0.96), was lower after nonseminomatous germ cell tumor (HR, 0.58; 95% CI, 0.35 to 0.96) and dec

147 (TGCTs), suggesting similar etiology between germ cell tumors in mouse and man.

148 several important developments in testicular germ cell tumors in the last year.

149 several important developments in testicular germ cell tumors in the past year is provided.

150 several important developments in testicular germ cell tumors in the past year.

151 several important developments in testicular germ cell tumors in the past year.

152 several important developments in testicular germ cell tumors in the past year.

153 to pesticides during the index pregnancy and germ-cell tumors in boys (OR = 0.2, 95% CI: 0.1, 1.0).

154 ides during the postnatal period and risk of germ-cell tumors in girls (OR = 2.3, 95% CI: 1.0, 5.2) a

155 or patients with intermediate- and poor-risk germ cell tumors, in whom 4 cycles of bleomycin, etoposi

156 ations in 1 of 14 nonseminomatous testicular germ-cell tumors, in 2 of 5 embryonal rhabdomyosarcomas,

157 dies show changes in the ethnic incidence of germ cell tumors; in particular, African-Americans have

158 iable region from 320 sequences expressed by germ cell tumor-infiltrating B cells revealed clear evid

159 confidence interval (CI): 2.65, 3.50), with germ cell tumors (IRR = 5.19, 95% CI: 2.67, 9.41), retin

160 minal residual masses after chemotherapy for germ cell tumors is both a feasible and safe alternative

161 ons between chlordane isomers and testicular germ cell tumors, it is reasonable to assume that chlord

162 Secondly, a subset of testicular germ cell tumors, known as non-seminomas, often contain

163 However, chemotherapy of germ-cell tumors led to the induction of anti-OCT4 immun

164 lignancies include lung cancer, skin cancer, germ cell tumors, leiomyosarcomas, cancers of the head a

165 is, pooled libraries (with testis), and in a germ cell tumor library.

166 scents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplat

167 contemporary management of malignant ovarian germ cell tumors (MOGCT).

168 , recent studies demonstrate that testicular germ cell tumor mortalities can vary significantly in di

169 e survival outcomes in metastatic testicular germ cell tumor (MT-GCT), but how the initial risk chang

170 intermediate risk, poor risk, and recurrent germ cell tumors need to be developed, while long-term t

171 iomarkers to differentiate non-germinomatous germ cell tumors (NGGCTs) from germinomas are critical,

172 r of 12 patients (33%) with nongerminomatous germ cell tumors (NGGCTs) survived without evidence of d

173 f patients with disseminated nonseminomatous germ cell tumor (NSGCT) managed under a postchemotherapy

174 management of patients with nonseminomatous germ cell tumor (NSGCT) who achieve a serologic and radi

175 nical stage (CS) IIA and IIB nonseminomatous germ cell tumor (NSGCT) with adenopathy more than 2 cm,

176 went PC-RPLND for metastatic nonseminomatous germ cell tumor (NSGCT).

177 eillance (AS) for testicular nonseminomatous germ cell tumors (NSGCT) is widely used.

178 y and surgery for metastatic nonseminomatous germ cell tumors (NSGCT) results in survival rates of gr

179 patients with poor-prognosis nonseminomatous germ cell tumors (NSGCT) treated with CBOP/BEP.

180 ients from 1989 to 2003 with nonseminomatous germ cell tumors (NSGCT) who underwent initial PC-RPLND

181 ovarian dysgerminoma and 37 non-seminomatous germ cell tumors (NSGCT).

182 with clinical stage I (CS1) nonseminomatous germ cell tumors (NSGCT); this study examined whether an

183 tients with clinical stage I nonseminomatous germ cell tumors (NSGCTs) have been managed with surveil

184 th pathologic stage (PS) IIA nonseminomatous germ cell tumors (NSGCTs) is 10%-20% but increases to >=

185 th poor-prognosis metastatic nonseminomatous germ cell tumors (NSGCTs).

186 birth of the index child were not related to germ-cell tumors (odds ratios (ORs) were 0.9 (95% CI: 0.

187 The most common malignant germ cell tumor of early childhood is the endodermal sin

188 .A 32-year-old man with a history of a mixed germ cell tumor of the testis presented with acute-onset

189 tic linkage to the development of testicular germ cell tumors of adolescents and adults (TGCTs), i.e.

190 Salvage therapy for disseminated germ cell tumors of all histologic subtypes with vinblas

191 Extragonadal germ cell tumors of infancy, one of the most common neon

192 rates that has been implicated in testicular germ cell tumors of mouse and human.

193 Germ cell tumors of the ovary constitute less than one p

194 tidisciplinary approach to the management of germ cell tumors of the testis has resulted in survival

195 tients with clinical stage I nonseminomatous germ cell tumors of the testis were entered on a surveil

196 marize the surgical management of metastatic germ cell tumors of the testis, highlighting the indicat

197 oma with other components of malignant mixed germ cell tumors of the testis.

198 Primary germ-cell tumors of the central nervous system are rare

199 mic, and brainstem encephalitis, and 78% had germ-cell tumors of the testis.

200 Like several other tumor types, germ cell tumors often harbor an immune cell infiltrate

201 ion of health care resources between ovarian germ cell tumor (OGCT) survivors and age/race/education-

202 Ovarian germ cell tumors (OGCTs) show a heterogeneity that is no

203 erived from the same element of the original germ cell tumor or the same progenitor cell.

204 odds ratio (OR) = 1.05; 95% CI: 1.01, 1.10]; germ cell tumors (OR = 1.16; 95% CI: 1.04, 1.29), partic

205 her RA-sensitive cell lines that were not of germ cell tumor origin.

206 ng regions of imbalance (SORI) in testicular germ cell tumors other than the 12p region, which has be

207 Preclinical and clinical developments in germ cell tumors over the past year are summarized.

208 the preclinical and clinical developments in germ cell tumors over the past year is presented.

209 GFBP-3 concentrations and risk of testicular germ-cell tumors (p > 0.05).

210 tudies highlight the complexities underlying germ cell tumor pathogenesis.

211 definite activity in this heavily pretreated germ cell tumor patient population.

212 oogenesis, leading to either an agametic or germ cell tumor phenotype.

213 ion of the resected tissue showed metastatic germ cell tumor predominantly consisting of a yolk sac e

214 chromosome 1p33-34, a region deleted in some germ cell tumors, raising the possibility that PTCH2 may

215 gy of nonseminomatous subtypes of testicular germ cell tumors remain to be established.

216 Significant challenges for poor-risk germ cell tumors remain.

217 n in postorchiectomy early-stage nonseminoma germ cell tumors remains a topic of debate.

218 Analysis of human germ cell tumors reveals similar gene expression changes

219 ors examined associations between testicular germ-cell tumor risk and circulating concentrations of i

220 Human germ cell tumors show a strong sensitivity to genetic ba

221 ized the immune cell infiltrate of all three germ cell tumor subtypes and defined the molecular chara

222 quences of therapies in long-term testicular germ cell tumor survivors are being further clarified.

223 To compare malignant ovarian germ cell tumor survivors with a matched control group o

224 a +/- necrosis (20%), viable nonteratomatous germ cell tumor +/- teratoma (41%), and secondary somati

225 TRs was found to be high in human and murine germ cell tumors (testicular teratocarcinomas) and low i

226 Patients with testicular germ cell tumor (TGCT) are at increased risk of developi

227 Complex genetic factors underlie testicular germ cell tumor (TGCT) development.

228 wide association (GWA) studies of testicular germ cell tumor (TGCT) have identified 18 susceptibility

229 Testicular germ cell tumor (TGCT) is the most common cancer in youn

230 Testicular germ cell tumor (TGCT) is the most common cancer in youn

231 Unconventional inheritance for testicular germ cell tumor (TGCT) risk both in humans and mice impl

232 exhibit male infertility, a known testicular germ cell tumor (TGCT) risk factor.

233 are the most potent modifiers of testicular germ cell tumor (TGCT) susceptibility in mice and rats.

234 enetic modifier known to suppress testicular germ cell tumor (TGCT) susceptibility in mice or humans.

235 etic variants act as modifiers of testicular germ cell tumor (TGCT) susceptibility in the 129/Sv mous

236 genome-wide association study for testicular germ cell tumor (TGCT), genotyping 307,666 SNPs in 730 c

237 distinct susceptibility loci for testicular germ cell tumor (TGCT).

238 ntify new susceptibility loci for testicular germ cell tumor (TGCT).

239 enome-wide association studies of testicular germ cell tumor (TGCT; 3,558 cases and 13,970 controls)

240 ked disparity in the incidence of testicular germ cell tumors (TGCT) among white and black men for a

241 Testicular germ cell tumors (TGCT) are considered a paradigm of che

242 Testicular germ cell tumors (TGCT) are sex limited, occurring only

243 Testicular germ cell tumors (TGCT) are the most common solid tumors

244 Testicular germ cell tumors (TGCT) are the most frequently diagnose

245 Testicular germ cell tumors (TGCT) generally respond well to chemot

246 Susceptibility to testicular germ cell tumors (TGCT) has a significant heritable comp

247 Testicular germ cell tumors (TGCT) have been expected to have a str

248 etic control of susceptibility to testicular germ cell tumors (TGCT) in humans or mice.

249 Testicular germ cell tumors (TGCT) originate from germ cells.

250 Testicular germ cell tumors (TGCT) represent the most common malign

251 isk factor for the development of testicular germ cell tumors (TGCT), but the initiating event linkin

252 also influences susceptibility to testicular germ cell tumors (TGCT), the most common testicular canc

253 ance and thereby increase risk of testicular germ cell tumors (TGCT).

254 ry networks in two major types of testicular germ cell tumors (TGCT): seminoma (SE) and non-seminoma

255 analyzed population-wide data on testicular germ-cell tumor (TGCT) status in 1,135,320 two-generatio

256 Testicular germ cell tumors (TGCTs) are classified into two main su

257 Testicular germ cell tumors (TGCTs) are highly responsive to and cu

258 Testicular germ cell tumors (TGCTs) are the most common solid cance

259 Testicular germ cell tumors (TGCTs) arise despite possessing high l

260 netic basis for susceptibility to testicular germ cell tumors (TGCTs) has been remarkably elusive.

261 ) gene enhances susceptibility to testicular germ cell tumors (TGCTs) in mice, in part by interacting

262 ement, and risk stratification of testicular germ cell tumors (TGCTs) in the past year.

263 The etiology of testicular germ cell tumors (TGCTs) is poorly understood, with cryp

264 ial is invariably associated with testicular germ cell tumors (TGCTs) of adolescents and adults, most

265 several important developments in testicular germ cell tumors (TGCTs) over the past year.

266 Testicular germ cell tumors (TGCTs) share germline ancestry but div

267 Susceptibility to spontaneous testicular germ cell tumors (TGCTs), a common cancer affecting youn

268 nderstanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability r

269 es also are misregulated in human testicular germ cell tumors (TGCTs), suggesting similar etiology be

270 Testicular germ cell tumors (TGCTs), the most common neoplasms of y

271 icancer drug for the treatment of testicular germ cell tumors (TGCTs).

272 ociated with an increased risk of testicular germ cell tumors (TGCTs).

273 crocalcifications do exist in roughly 50% of germ cell tumors the majority of men with testicular mic

274 to the known hypersensitivity of testicular germ cell tumors to chemotherapy.

275 evance to the hypersensitivity of testicular germ cell tumors to cisplatin, are discussed.

276 nship to other components of malignant mixed germ cell tumors to gain potential insight into the hist

277 but were indeed found in 7% of 43 testicular germ cell tumor trios; this percentage exceeds backgroun

278 described previously in ARF-null mice (mixed germ cell tumor, Triton tumor, and histiocytic sarcoma)

279 o stem and progenitor cells of patients with germ cell tumors undergoing autologous transplantation.

280 ed its expression levels in human testicular germ cell tumors using patient tissues, model cell lines

281 ion studies were extended to patient-derived germ cell tumors using total cellular RNA Northern analy

282 ar OS in patients with a primary mediastinal germ cell tumor was 77.1% (95% CI, 34.5% to 93.9%) compa

283 high-dose etoposide as therapy for relapsed germ cell tumors was associated with a 2.6% risk of deve

284 o search for clues into the genesis of human germ cell tumors, we compared the expression profiles of

285 y associated with lymphomas and some ovarian germ cell tumors, we present a case of calcitriol overpr

286 atients with a history of or newly diagnosed germ cell tumors were evaluable.

287 Malignant germ cell tumors were identified in 2.8% (31 of 1097) of

288 total of 304 men with advanced disseminated germ cell tumors were randomly allocated to receive four

289 and 90 of 149 patients with nonseminomatous germ-cell tumors were disease-free.

290 49 patients with moderate-stage disseminated germ-cell tumors were randomized to either three or four

291 itive treatment of patients with nonseminoma germ cell tumor, whereas radiotherapy, as a standard tre

292 Twenty patients with germ cell tumor who had persistent disease or relapse fr

293 All CS I patients with nonseminomatous germ cell tumors who underwent RPLND at Indiana Universi

294 iectomy, and pathology showed a 1.5-cm mixed germ cell tumor with 85% embryonal, 10% yolk sac tumor,

295 The treatment of advanced testicular germ cell tumors with cisplatin combination chemotherapy

296 Germ cell tumors with EC components were significantly m

297 cond-line therapy in patients with recurrent germ cell tumors with previous treatment with cisplatin

298 to 100) of patients with favorable prognosis germ-cell tumor with an initial HCG of < or = 1,000 mIU/

299 mcitabine is an active regimen in refractory germ cell tumors, with an acceptable toxicity profile.

300 4 mRNA (P < or = 0.0179) than other examined germ cell tumors without EC components.